Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

67.81 -2.53 (-3.60%)

Delayed Quote Updated: 1:36 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Tempus Announces Multi-Year Collaboration with Moderna and Merck

October 07, 2026

From Tempus

Via Business Wire

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

October 01, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

September 28, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus AI Chief Accounting Officer Sells $529,650 of Stock ↗

September 24, 2026

Sale follows 30% rebound in the stock year to date.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI (NASDAQ:TEM) Delivers Mixed Q2 Results with EPS Beat, Stock Slips in After-Hours Trading ↗

July 30, 2026

Via Chartmill

Topics Artificial Intelligence

Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion ↗

September 21, 2026

Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its...

Via MarketBeat

Topics Artificial Intelligence

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

September 21, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

September 11, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

September 09, 2026

From Tempus AI, Inc.

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

September 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 04, 2026

From Tempus AI, Inc.

Via Business Wire

September 03, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Tempus AI Director Nadja West Sells 3,000 Shares for $207,000 ↗

September 02, 2026

Sale executed under pre-established Rule 10b5-1 trading plan adopted in May, leaving West with 31,981 shares and a 0.0183% ownership stake.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Cathie Wood Invested Roughly $1.4 Billion of Ark Invest's Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks ↗

August 28, 2026

Wood is known for being a tech-first investor.

Via The Motley Fool

Topics Artificial Intelligence ETFs Earnings

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

August 24, 2026

From Tempus AI, Inc.

Via Business Wire

Why Tempus AI Skyrocketed This Week ↗

August 23, 2026

Tempus AI's latest acquisition is looking like a great move.

Via The Motley Fool

Topics Artificial Intelligence Stocks

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know ↗

August 22, 2026

West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade ↗

August 22, 2026

Polovin's sale of 30,075 shares was non-discretionary and tied to tax withholding from RSU vesting.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know ↗

August 22, 2026

Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing ↗

August 22, 2026

This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened ↗

August 22, 2026

These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter. ↗

August 22, 2026

This sale was non-discretionary, executed to cover tax withholding from RSU vesting.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know ↗

August 22, 2026

This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

AI Found an Influenza Target That Survives Viral Mutation

August 10, 2026

Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)

From Equity Insider

Via GlobeNewswire

Why Is Tempus AI Stock Surging on Friday? ↗

August 07, 2026

Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.

Via Benzinga

Topics Artificial Intelligence

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

August 04, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus AI Q2 Earnings Call Highlights ↗

July 31, 2026

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial...

Via MarketBeat

Topics Artificial Intelligence Earnings

Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset? ↗

July 31, 2026

Tempus AI Inc. (NASDAQ: TEM) shares are trading lower Friday as traders digest post-earnings reset in expectations.

Via Benzinga

Topics Artificial Intelligence

Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares? ↗

July 31, 2026

Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus Reports Second Quarter 2026 Results

July 30, 2026

From Tempus AI, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.